BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27259304)

  • 1. High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer.
    Li X; Yang Y; Zhang H; Yue W; Zhang T; Lu B; Li J; Liu Z; Wang Q; Gao Y; Hu A; Zhang H; Shi H; Hu F; Li B
    Cell Biochem Biophys; 2015 Dec; 73(3):631-7. PubMed ID: 27259304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of phosphatase and tensin homolog expression predict favorable prognosis in patients with non-small cell lung cancer.
    Li XB; Yang Y; Zhang HQ; Yue WT; Zhang TM; Lu BH; Li J; Liu Z; Wang QH; Gao Y; Hu AM; Zhang HM; Shi HL; Hu FB; Li BL
    Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2231-9. PubMed ID: 26166648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
    Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
    Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
    Wang D; Hao T; Pan Y; Qian X; Zhou D
    Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
    Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
    Rulle U; Tsourti Z; Casanova R; Deml KF; Verbeken E; Thunnissen E; Warth A; Cheney R; Sejda A; Speel EJ; Madsen LB; Nonaka D; Navarro A; Sansano I; Marchetti A; Finn SP; Monkhorst K; Kerr KM; Haberecker M; Wu C; Zygoura P; Kammler R; Geiger T; Gendreau S; Schulze K; Vrugt B; Wild P; Moch H; Weder W; Ciftlik AT; Dafni U; Peters S; Bubendorf L; Stahel RA; Soltermann A
    J Thorac Oncol; 2018 Dec; 13(12):1851-1863. PubMed ID: 30240851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer.
    Hu J; Liu YL; Piao SL; Yang DD; Yang YM; Cai L
    Lung Cancer; 2012 Sep; 77(3):593-9. PubMed ID: 22717106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma.
    Zolota VG; Tzelepi VN; Leotsinidis M; Zili PE; Panagopoulos ND; Dougenis D; Tsamandas AC; Scopa CD
    J Surg Res; 2010 Dec; 164(2):256-65. PubMed ID: 19691991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
    Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
    Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
    Kim HS; Kim GY; Lim SJ; Kim YW
    Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature.
    Xiao J; Hu CP; He BX; Chen X; Lu XX; Xie MX; Li W; He SY; You SJ; Chen Q
    Oncotarget; 2016 Sep; 7(36):57832-57840. PubMed ID: 27506936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
    Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
    Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis.
    Zhao Y; Zheng R; Li J; Lin F; Liu L
    Thorac Cancer; 2017 May; 8(3):203-213. PubMed ID: 28263037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.